Graham C H, Kobayashi H, Stankiewicz K S, Man S, Kapitain S J, Kerbel R S
Cancer Research Division, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
J Natl Cancer Inst. 1994 Jul 6;86(13):975-82. doi: 10.1093/jnci/86.13.975.
Clinical drug resistance is either intrinsic (de novo) or often acquired rapidly in conjunction with chemotherapy. By contrast, the selection of drug-resistant mutant cell lines in monolayer culture systems is usually a more protracted process. Sublines of mouse EMT-6 mammary tumor cells selected for resistance to various alkylating agents in vivo after serial passage into syngeneic mice manifest their resistance in vitro only when cultured as three-dimensional multicellular aggregates or spheroids.
We examined whether a single exposure of mouse EMT-6 or human MDA-MB-231 breast cancer cells to alkylating agents in vitro is sufficient for the induction of a resistance phenotype, which may be detected by re-applying the drugs to cells grown as three-dimensional aggregates.
Mouse EMT-6 and human MDA-MB-231 breast cancer cells cultured as three-dimensional aggregates were exposed to a single dose of alkylating agent for 1-5 days. Aggregates were dispersed, and cells were plated as monolayer cultures for up to 8 weeks to allow for recovery. Colony-forming ability was assessed after a subsequent alkylating-agent exposure of cells cultured as monolayers or three-dimensional aggregates.
A single in vitro exposure to 12.5-microM cisplatin (CDDP) for 5 days or 25 microM 4-hydroperoxycyclophosphamide (4-O2H CTX) for 1 or 3 days without changing the medium was sufficient to induce transient but substantial resistance in EMT-6 cells as determined by clonogenic assays. Such resistance was not detected when monolayer cell cultures were used. The concentration of 4-O2H-CTX and the length of time the cells remained in three-dimensional culture after initial exposure to this drug was associated with the degree of subsequent drug resistance of cells grown as three-dimensional cultures. Furthermore, this acquired resistance after a single drug exposure was accompanied by changes in the three-dimensional architecture of the cell aggregates, which now formed much more compact multicellular spheroids. Similarly, a single exposure to 4-O2H-CTX was enough to bring about resistance in MDA-MB-231 cells detectable only in three-dimensional cultures, as well as the change in three-dimensional architecture.
Rapid acquisition of resistance likely represents a physiologic mechanism of adaptation operative at the multicellular level rather than a stable genetic change and may be one of the reasons for the rapid development of drug resistance acquired by tumors in vivo.
In vivo drug exposure may result in transient and low levels of drug resistance that may nevertheless be clinically relevant.
临床耐药性要么是内在的(原发性的),要么常常在化疗过程中迅速获得。相比之下,在单层培养系统中选择耐药突变细胞系通常是一个更为漫长的过程。将小鼠EMT-6乳腺肿瘤细胞连续传代至同基因小鼠体内后,筛选出对各种烷化剂具有抗性的亚系,只有当这些细胞作为三维多细胞聚集体或球体培养时,才会在体外表现出抗性。
我们研究了小鼠EMT-6或人MDA-MB-231乳腺癌细胞在体外单次暴露于烷化剂是否足以诱导出抗性表型,这种抗性表型可通过将药物重新应用于作为三维聚集体生长的细胞来检测。
将作为三维聚集体培养的小鼠EMT-6和人MDA-MB-231乳腺癌细胞暴露于单剂量烷化剂1至5天。将聚集体分散,细胞接种为单层培养物长达8周以使其恢复。在随后将细胞作为单层或三维聚集体培养并暴露于烷化剂后,评估集落形成能力。
在不更换培养基的情况下,将EMT-6细胞体外单次暴露于12.5 μM顺铂(CDDP)5天或25 μM 4-氢过氧环磷酰胺(4-O2H CTX)1天或3天,足以通过克隆形成试验诱导出短暂但显著的抗性。当使用单层细胞培养时未检测到这种抗性。4-O2H-CTX的浓度以及细胞在初次暴露于该药物后在三维培养中保持的时间长度与作为三维培养生长的细胞随后的耐药程度相关。此外,单次药物暴露后获得的这种抗性伴随着细胞聚集体三维结构的变化,现在形成了更为紧密的多细胞球体。同样,单次暴露于4-O2H-CTX足以使MDA-MB-231细胞产生仅在三维培养中可检测到的抗性,以及三维结构的变化。
快速获得抗性可能代表了一种在多细胞水平起作用的生理适应机制,而不是一种稳定的基因变化,并且可能是肿瘤在体内快速产生耐药性的原因之一。
体内药物暴露可能导致短暂且低水平的耐药性,但其仍可能具有临床相关性。